The Journal of the Chinese Academy of Engineering released an article on the mechanism of action of Pianzaihuang in the treatment of fatty liver disease, which has attracted attention.

Recently, an article published on the official account of the Chinese Academy of Engineering's main publication "Engineering" revealed that a research team led by Professor Yu Jun from the Chinese University of Hong Kong has, for the first time, proven that "Pien Tze Huang may be an effective drug for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD)." The paper points out that NAFLD is a significant global health issue, affecting 25% of the world's population, with a prevalence rate as high as 34% in Asian populations. Around 20% of NAFLD patients progress to non-alcoholic steatohepatitis (NASH), which is a severe stage of NAFLD characterized by liver cell damage, hepatitis, and fibrosis. Although traditional Chinese medicine has been widely recognized for its multi-target and multi-pathway mechanisms, the therapeutic effect of Pien Tze Huang on NASH has not yet been conclusively determined.